News from boehringer ingelheim A wide array of domestic and global news stories; news topics include politics / government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages, as well.

Feb 09, 2016, 08:00 ET
STIOLTO RESPIMAT

Newly Published Head-to-Head Data Show STIOLTO RESPIMAT Improved Lung Function Across Range of Measures

Boehringer Ingelheim Pharmaceuticals, Inc. today announced the publication of data that show STIOLTO RESPIMAT improved lung function across a range...

Feb 03, 2016, 08:00 ET
SPIRIVA RESPIMAT

SPIRIVA RESPIMAT Now Available in the U.S. for Maintenance Treatment of Asthma in Adults and Adolescents

 Boehringer Ingelheim Pharmaceuticals, Inc. today announced that SPIRIVA RESPIMAT is now available by prescription for the treatment of asthma...

Jan 25, 2016, 08:30 ET
Eli Lilly and Company logo.

U.S. FDA Accepts Filing of Cardiovascular Outcomes Data for Jardiance® (empagliflozin)

The U.S. Food and Drug Administration (FDA) accepted a supplemental New Drug Application for Jardiance® (empagliflozin) based on...

Dec 21, 2015, 08:00 ET
Boehringer Ingelheim

Boehringer Ingelheim's third generation EGFR TKI, BI 1482694, receives FDA Breakthrough Therapy Designation for treatment of patients with non-small cell lung cancer

Boehringer Ingelheim today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to its...

Dec 14, 2015, 08:00 ET

First Multinational Study Initiated to Evaluate OFEV® (nintedanib) with Add-on of pirfenidone in the Treatment of Idiopathic Pulmonary Fibrosis

 Boehringer Ingelheim Pharmaceuticals, Inc. today announced the initiation of a new 12-week study (ClinicalTrials.gov Identifier: NCT02579603)...

Dec 08, 2015, 08:00 ET

New Phase III Study of Nintedanib in People with Systemic Sclerosis and Lung Fibrosis Launched

 Boehringer Ingelheim announced today that the first person has been enrolled in the SENSCIS™ (Safety and Efficacy of Nintedanib in...

Dec 02, 2015, 08:00 ET
Boehringer Ingelheim

Boehringer Ingelheim and MD Anderson Cancer Center join forces to discover new treatment approaches for pancreatic cancer

 Boehringer Ingelheim and The University of Texas MD Anderson Cancer Center today announced a collaboration focused on developing innovative...

Nov 23, 2015, 10:24 ET

FDA Approves Pradaxa® (dabigatran etexilate mesylate) for Prophylaxis of Deep Venous Thrombosis (DVT) and Pulmonary Embolism (PE) after Hip Replacement Surgery

 Boehringer Ingelheim Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) approved...

Nov 18, 2015, 11:30 ET
Nancy Di Dia, chief diversity and inclusion officer, Boehringer Ingelheim

Boehringer Ingelheim Awarded Perfect Score on Human Rights Campaign Foundation's Corporate Equality Index

 Boehringer Ingelheim announced today that it has been recognized on the 2016 Corporate Equality Index (CEI). This is the eighth time that the...

Nov 13, 2015, 04:00 ET

New Analyses Further Add to the Efficacy and Safety Profile of OFEV® (nintedanib) in Idiopathic Pulmonary Fibrosis (IPF)

Boehringer Ingelheim Pharmaceuticals, Inc. today announced the presentation of new analyses of OFEV for the treatment of idiopathic pulmonary...

Nov 10, 2015, 08:30 ET
The Boehringer Ingelheim group is one of the world's 20 leading pharmaceutical companies

Boehringer Ingelheim Announces Completed Enrollment of Phase III Clinical Trial for Biosimilar Candidate to Adalimumab

 Boehringer Ingelheim today announced it has completed enrollment for the pivotal Phase III trial (NCT02137226) of BI695501, a biosimilar...

Nov 10, 2015, 08:01 ET

Boehringer Ingelheim partners with leading scientific institutions in inflammatory bowel disease research

 Boehringer Ingelheim today announced new collaborations with four major scientific partners to enrich research and development of novel...

Nov 09, 2015, 14:45 ET
Nov 09, 2015, 14:00 ET

Real-World Analysis of More Than 44,000 Patients Reinforces Safety and Effectiveness of Pradaxa® (dabigatran etexilate mesylate) in Routine Clinical Care

 Brigham and Women's Hospital in Boston and Boehringer Ingelheim today announced the results of a new interim analysis from a long-term study...

Nov 09, 2015, 10:45 ET
Eli Lilly and Company logo

New Jardiance® (empagliflozin) data show improved CV outcomes regardless of heart failure status at baseline

 New sub-analysis data presented today showed the reduction in risk for hospitalization for heart failure or cardiovascular death with...

Nov 08, 2015, 10:17 ET

Boehringer Ingelheim Highlights Latest Community and Research Initiatives in Advancing Anticoagulation Care at American Heart Association (AHA) Scientific Sessions 2015

 Today at the American Heart Association (AHA) Scientific Sessions 2015, Boehringer Ingelheim Pharmaceuticals, Inc. announced two key...

Nov 06, 2015, 08:00 ET
Eli Lilly and Company logo.

EMPA-REG OUTCOME®: Top-line renal data to be presented during American Society of Nephrology (ASN) Kidney Week 2015

 Boehringer Ingelheim Pharmaceuticals, Inc. (BIPI) and Eli Lilly and Company (NYSE: LLY) today announced that top-line renal results from the...

Nov 02, 2015, 09:00 ET
Boehringer Ingelheim Pharmaceuticals, Inc. headquarters in Ridgefield, Connecticut

Boehringer Ingelheim Recognized on Science Magazine's 2015 Top Employer List

 Boehringer Ingelheim announced today that it has been recognized by Science magazine for the eleventh consecutive year as a top company to...

Oct 28, 2015, 08:30 ET

Boehringer Ingelheim's Biosimilar Candidate Demonstrated Pharmacokinetic Bioequivalence to Adalimumab

Boehringer Ingelheim today announced results from a Phase I study (NCT02045979) of its biosimilar candidate (BI695501) for adalimumab (AbbVie's...